People | July 11, 2022
Piramal Pharma strengthens board by inducting three new board members
The appointments will add to the well-diversified experience that currently exists on the PPL board.
The appointments will add to the well-diversified experience that currently exists on the PPL board.
The company has a total sales of Rs. 25.8 crore during FY 21-22 and Rs. 26.4 crore during FY 20-21.
Multiples is the first private equity (PE) investor in the company
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
A growing portfolio of chemicals is part of a larger quality management system that sets new standards in bioprocessing
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
He will continue to lead business in LATAM and Asia regions in this new role
The companies plan to use the proceeds to retire debt and expand operations
Occupancy is expected to be in the range of 60-62% while Average Revenue Per Occupied Bed (ARPOB) is expected to expand by least 6% in FY2022
The current round is led by IIFL Asset Management (IIFL AMC) along with investment from existing investors InvestCorp and Bessemer Venture Partners (BVP)
Subscribe To Our Newsletter & Stay Updated
